Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061.
Ann Oncol. 2019.
PMID: 30796821
Free article.
Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators.
Miles D, et al. Among authors: du toit y.
Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2.
Ann Oncol. 2021.
PMID: 34224826
Free article.
Clinical Trial.
Item in Clipboard
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D, Knott A, Song C, Cortazar P.
Swain SM, et al. Among authors: du toit y.
Cancers (Basel). 2022 Oct 15;14(20):5051. doi: 10.3390/cancers14205051.
Cancers (Basel). 2022.
PMID: 36291835
Free PMC article.
Item in Clipboard
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Polito L, Shim J, Hurvitz SA, Dang CT, Knott A, Du Toit Y, Restuccia E, Sanglier T, Swain SM.
Polito L, et al. Among authors: du toit y.
JCO Oncol Pract. 2023 Jul;19(7):435-445. doi: 10.1200/OP.22.00565. Epub 2023 May 11.
JCO Oncol Pract. 2023.
PMID: 37167571
Free PMC article.
Item in Clipboard
Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA, Press DJ, Hansen SA, Kim E, Du Toit Y, Fung A.
Sussell JA, et al. Among authors: du toit y.
Adv Ther. 2023 Sep;40(9):3857-3874. doi: 10.1007/s12325-023-02554-6. Epub 2023 Jun 26.
Adv Ther. 2023.
PMID: 37358705
Free PMC article.
Item in Clipboard
eCALIBRATOR: A Comparative Tool to Identify Key Genes and Pathways for Eucalyptus Defense Against Biotic Stressors.
du Toit Y, Coles DW, Mewalal R, Christie N, Naidoo S.
du Toit Y, et al.
Front Microbiol. 2020 Feb 17;11:216. doi: 10.3389/fmicb.2020.00216. eCollection 2020.
Front Microbiol. 2020.
PMID: 32127794
Free PMC article.
Item in Clipboard
Cite
Cite